On Jul. 29, 2021, Emergent BioSolutions announced that the FDA had begun allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s COVID-19 vaccine bulk drug substance. This resumption of manufacturing followed extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.